PE20091451A1 - Derivados de imidazol como inhibidores de cinesina (ksp) - Google Patents

Derivados de imidazol como inhibidores de cinesina (ksp)

Info

Publication number
PE20091451A1
PE20091451A1 PE2008002064A PE2008002064A PE20091451A1 PE 20091451 A1 PE20091451 A1 PE 20091451A1 PE 2008002064 A PE2008002064 A PE 2008002064A PE 2008002064 A PE2008002064 A PE 2008002064A PE 20091451 A1 PE20091451 A1 PE 20091451A1
Authority
PE
Peru
Prior art keywords
amino
alkyl
kinesine
ksp
carboxyl
Prior art date
Application number
PE2008002064A
Other languages
English (en)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Annette Olga Walter
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091451A1 publication Critical patent/PE20091451A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDO A COMPUESTOS DE IMIDAZOL DE FORMULA I, DONDE R1 ES AMINO-ACILO, ACIL-AMINO, CARBOXILO ENTRE OTROS; R2 ES H, ALQUILO Y ARILO; Ra ES L-A1, DONDE L ES -S(O)q-, Y ALQUILENO DE 1 A 5 ATOMOS DE CARBONO OPCIONALMENTE SUSTITUIDO CON HIDROXILO, HALOGENO O ACIL-AMINO; q ES 1 O 2; A1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R6 ES HETEROCICLICO, ARILO Y HETEROARILO, OPCIONALMENTE SUSTITUIDOS CON -(R8)m; DONDE R8 ES CIANO, ALQUILO, ALQUENILO, ENTRE OTROS; m ES UN ENTERO DE 1 A 3, Rb ES R4 O R5; DONDE R4, ES H, ALQUILO LINEAL, -ALQUILENO-AMINO-ACILO, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; RC ES R3 Y -C(O)-N(R13)-(R14), DONDE R3 ES H, Y -X-A; DONDE X ES -C(O)-, -C(S), -S(O), ENTRE OTROS; A ES H, CARBOXILO, CARBOXIL-ESTER, ENTRE OTROS; R13 Y R14 SON CADA UNO H, HIDROXILO, ALQUILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION PARA UNA COMPOSICION QUE LO CONTIENE. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE HUSO DE CINESINA (KSP), SIENDO UTIL EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS TAL COMO CANCER
PE2008002064A 2007-12-14 2008-12-12 Derivados de imidazol como inhibidores de cinesina (ksp) PE20091451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
PE20091451A1 true PE20091451A1 (es) 2009-10-19

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002064A PE20091451A1 (es) 2007-12-14 2008-12-12 Derivados de imidazol como inhibidores de cinesina (ksp)

Country Status (30)

Country Link
US (2) US8252832B2 (es)
EP (1) EP2229170B1 (es)
JP (1) JP5501976B2 (es)
KR (1) KR20100098394A (es)
CN (1) CN101939005B (es)
AR (1) AR069676A1 (es)
AU (1) AU2008337570B2 (es)
BR (1) BRPI0821248A2 (es)
CA (1) CA2708822A1 (es)
CL (1) CL2008003707A1 (es)
CO (1) CO6290651A2 (es)
CR (1) CR11412A (es)
DO (1) DOP2010000175A (es)
EA (1) EA018014B1 (es)
EC (1) ECSP10010248A (es)
ES (1) ES2459442T3 (es)
GE (1) GEP20125647B (es)
GT (1) GT201000172A (es)
IL (1) IL205831A0 (es)
MA (1) MA31872B1 (es)
MY (1) MY150214A (es)
NI (1) NI201000091A (es)
NZ (1) NZ585142A (es)
PA (1) PA8807801A1 (es)
PE (1) PE20091451A1 (es)
SM (1) SMP201000095B (es)
TN (1) TN2010000204A1 (es)
TW (1) TW200930704A (es)
UY (1) UY31532A1 (es)
WO (1) WO2009077448A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
AU2016282723B2 (en) * 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
CN101622247A (zh) 2007-01-05 2010-01-06 诺瓦提斯公司 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物

Also Published As

Publication number Publication date
SMAP201000095A (it) 2010-09-10
IL205831A0 (en) 2010-11-30
EA018014B1 (ru) 2013-04-30
CR11412A (es) 2010-06-30
GEP20125647B (en) 2012-09-25
KR20100098394A (ko) 2010-09-06
TW200930704A (en) 2009-07-16
BRPI0821248A2 (pt) 2015-06-16
PA8807801A1 (es) 2009-07-23
ECSP10010248A (es) 2010-07-30
CN101939005B (zh) 2015-12-16
US20090239922A1 (en) 2009-09-24
JP2011506402A (ja) 2011-03-03
MY150214A (en) 2013-12-13
CL2008003707A1 (es) 2009-06-05
DOP2010000175A (es) 2010-06-30
US8664256B2 (en) 2014-03-04
AU2008337570B2 (en) 2012-04-05
GT201000172A (es) 2012-04-30
NI201000091A (es) 2011-03-15
JP5501976B2 (ja) 2014-05-28
ES2459442T3 (es) 2014-05-09
NZ585142A (en) 2012-03-30
CA2708822A1 (en) 2009-06-25
MA31872B1 (fr) 2010-11-01
EP2229170A1 (en) 2010-09-22
US8252832B2 (en) 2012-08-28
UY31532A1 (es) 2009-08-03
CN101939005A (zh) 2011-01-05
SMP201000095B (it) 2011-09-09
EA201000900A1 (ru) 2011-02-28
AR069676A1 (es) 2010-02-10
WO2009077448A1 (en) 2009-06-25
TN2010000204A1 (en) 2011-11-11
EP2229170B1 (en) 2014-01-22
AU2008337570A1 (en) 2009-06-25
US20130012560A1 (en) 2013-01-10
CO6290651A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
PE20091451A1 (es) Derivados de imidazol como inhibidores de cinesina (ksp)
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR088449A1 (es) Benzilindazoles sustituidos
PE20140236A1 (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
AR076838A1 (es) Sulfonamidas nematocidas
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20141974A1 (es) Compuestos de heterociclilo
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
MX2012006994A (es) Agente antiplaquetas novedoso.
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20070517A1 (es) Derivados de imidazol como agentes inhibidores de la sintasa de aldosterona y aromatasa
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
PE20140378A1 (es) Compuestos y composiciones como inhibidores de la trk
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
AR090005A1 (es) Imidazo[1,2-a]pirimidinas y piridinas sustituidas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed